Search hospitals

>

New Jersey

>

Newark

Newark Beth Israel Medical Center

Claim this profile

Newark, New Jersey 07112

Global Leader in Breast Cancer

Global Leader in Brain Tumor

Conducts research for Cancer

Conducts research for Lung Cancer

Conducts research for Leukemia

388 reported clinical trials

22 medical researchers

Photo of Newark Beth Israel Medical Center in NewarkPhoto of Newark Beth Israel Medical Center in NewarkPhoto of Newark Beth Israel Medical Center in Newark

Summary

Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Brain Tumor, Cancer, Lung Cancer, Leukemia and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 540 conditions. There are 22 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Mridula George, MD.

Area of expertise

1

Breast Cancer

Global Leader

Newark Beth Israel Medical Center has run 56 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
PR positive
2

Brain Tumor

Global Leader

Newark Beth Israel Medical Center has run 33 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Newark Beth Israel Medical Center

Breast Cancer

Brain Tumor

Lung Cancer

Testicular cancer

Colon Cancer

Wilms Tumor

Cancer

Breast cancer

Heart Disease

Heart Failure

Image of trial facility.

Fluoropyrimidine Dose-Adjustment

for Colorectal Cancer

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.

Recruiting

3 awards

Phase 4

2 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Newark Beth Israel Medical Center?

Where is Newark Beth Israel Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Newark Beth Israel Medical Center accept?

What awards or recognition has Newark Beth Israel Medical Center received?